Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE STEMI for Seniors)
- Conditions
- Myocardial Infarction
- Registration Number
- NCT02939976
- Lead Sponsor
- David Kong, M.D.
- Brief Summary
Patients with partially blocked blood vessel(s) in their heart may need a medical procedure called "Percutaneous Coronary Intervention (PCI)" to open the narrowed blood vessel(s). The purpose of this study is to simultaneously address four potential advances in ST-Elevation Myocardial Infarction (STEMI) care for patients at least 65 years old. The investigators are looking to see if these advances can improve the outcome for these patients.
1. Opening the arteries with a Medtronic stent
2. Radial access (from wrist) success with a Medtronic stent
3. Checking the percent of blockage in the diseased artery/arteries using Volcano guide wires.
4. Reduced bleeding and vascular complications with radial arterial access for primary PCI in STEMI.
- Detailed Description
Multicenter, randomized, open-label, unblinded, active and historical-controlled trial in which approximately 875 seniors undergoing urgent PCI from approximately 70 centers will be enrolled. All consented subjects will undergo attempted radial arterial access.
For DES (Drug Eluting Stent) eligible patients without randomization exclusion criteria and with multi-vessel disease identified during initial angiogram will be randomized by site in a ratio of 1:1 to IRA-only revascularization or iFR-guided complete revascularization. After randomization, subjects with stable TIMI-3 flow established in the IRA using the protocol specified treatment will proceed with the randomized procedure. Subjects in whom IRA reperfusion with TIMI-3 flow is not achieved will be treated according to clinical best practice standard of care independent of randomized procedure assignment and will not be considered protocol violations. These patients will be followed identically to all study patients.
After stent implantation, subjects will be contacted for follow-up at 30 days by the enrolling site and at 1 year by the DCRI Call Center.
Primary endpoint results will be reported after all subjects have completed 1 year (12 months) of clinical follow-up.
STEMI patients eligible for radial access:
* DES Eligible with single vessel Coronary Artery Disease (CAD) will receive DES to IRA
* DES Eligible with Multi-vessel CAD will randomize 1:1 to IRA-only revascularization or Instantaneous Wave Free Radio (iFR)-guided complete revascularization
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 427
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Adjudicated 1-year Infarct-related Artery Major Adverse Cardiac and Cerebrovascular Event (MACE) 1 year Defined as cardiac death, infarct artery target-vessel MI, or ischemia-driven index infarct related vessel revascularization (IIVR) by percutaneous or surgical methods.
Adjudicated 1-year Modified CvLPRIT (Complete Versus Lesion-only Primary PCI Trial) MACE 1 year Defined as all-cause mortality, recurrent MI, heart failure (requiring hospitalization or 12 hour ER visit) or ischemia-driven revascularization for all treated arteries.
Estimate of the Incidence Rate of Radial Artery Occlusion (RAO) 30 day Primary Observational Endpoint - Stratified by whether or not the Terumo TR Band was employed (use of the TR Band is recommended not required)
- Secondary Outcome Measures
Name Time Method Adjudicated Death (All Causes) Day 31 to 1 year Adjudicated Nonfatal (re-) MI Day 31 to 1 year Efficacy endpoint
Adjudicated Cardiac Death Day 31 to 1 year Efficacy endpoint
Adjudicated Nonfatal (re-) MI Myocardial (Infarction) Baseline to 30 days Efficacy endpoint
Adjudicated Index Infarct Related Vessel (re-) MI Day 31 to 1 year Efficacy endpoint
Adjudicated Index Infarct Related Lesion Revascularization (IILR) (Ischemia Driven) Day 31 to 1 year Efficacy endpoint
Adjudicated Index Infarct Vessel Revascularization (IIVR) (Ischemia Driven) Day 31 to 1 year Efficacy endpoint
Adjudicated Academic Research Consortium (ARC) Definite/Probable Stent Thrombosis 1 year (>30 days post stent) Safety endpoint
Adjudicated Academic Research Consortium (ARC) Definite Stent Thrombosis 1 year (>30 days post stent) Safety endpoint
Adjudicated Stroke Day 31 to 1 year Adjudicated Cardiac Death (All Causes) Day 31 to 1 year Incidence Rate of Access Success During procedure Access success is defined as successfully deploying the stent through the right or left radial artery stratified by whether or not Terumo Slender GlideSheath was employed
Heart Failure (Requiring Hospitalization or 12 Hour ER Visit) Day 31 to 1 year Ischemia-driven Revascularization for Index Infarct Vessel Revascularization (IIVR) or Any Treated Index Non-infarct Related Vessels (INIVR) 30 days Incidence of RAO, Stratified by Whether or Not the Terumo TR Band Was Employed in Combination With GlideSheath Slender 30 days Secondary Observational Endpoint
Site Reported Time to Achieve Hemostasis Post-procedure Secondary Observational Endpoint - Time to hemostasis stratified by whether the Terumo TR Band was employed
Incidence Rate of Cross Over From the Initial Access Point to Another Stratified by Whether or Not Terumo Slender GlideSheath Was Employed During procedure
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Duke Clinical Research Institute
🇺🇸Durham, North Carolina, United States
Duke Clinical Research Institute🇺🇸Durham, North Carolina, United States